Ms. Kristina Hachey reports

THERALASE GRANTS STOCK OPTIONS

Theralase Technologies Inc. has granted stock options.

The company has granted an aggregate of seven million stock options to eligible participants pursuant to the company's stock option plan. The options are exercisable at a price of 26.5 cents per common share, vest over a three-year period and expire five years from the date of grant. The stock option grant is subject to acceptance by the TSX Venture Exchange.

About Theralase Technologies Inc.

Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

We seek Safe Harbor.